| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
Fluorogestone acetate targets the progesterone receptor. By mimicking the action of progesterone and binding to nuclear progesterone receptors, it regulates gene expression. Its primary biological effect is the inhibition of luteinizing hormone (LH) release from the pituitary gland, thereby preventing ovulation.
|
|---|---|
| ln Vitro |
In vitro studies demonstrate that fluorogestone acetate binds to progesterone receptors with high affinity, activating receptor-mediated gene transcription. The compound’s progestational activity is comparable to natural progesterone, and it effectively mimics progesterone’s effects on target tissues, including the reproductive tract and pituitary gland.
|
| ln Vivo |
Fluorogestone acetate effectively inhibits ovulation and synchronizes the estrous cycle in cattle by suppressing LH release from the pituitary gland. It is widely used in veterinary medicine for reproductive synchronization protocols to manage breeding schedules in livestock.
|
| Enzyme Assay |
For non-cellular receptor binding assays, fluorogestone acetate’s affinity for the progesterone receptor can be evaluated using radioligand binding studies. Progesterone receptor-containing cell extracts or purified receptor preparations are incubated with radiolabeled progesterone and varying concentrations of fluorogestone acetate. Binding displacement curves are generated to determine IC50 and Ki values for receptor binding.
|
| Cell Assay |
In vitro cellular assays for fluorogestone acetate involve treating progesterone receptor-positive cell lines with the compound and measuring receptor-mediated transcriptional activity. Reporter gene assays using progesterone response element (PRE)-luciferase constructs are commonly used. Cells are treated with varying concentrations of fluorogestone acetate, and luciferase activity is measured to quantify receptor activation.
|
| Animal Protocol |
In vivo animal experiments for fluorogestone acetate are conducted primarily in cattle and other livestock species. Animals are treated with the compound according to reproductive synchronization protocols. Efficacy is assessed by monitoring estrous cycle synchronization, ovulation inhibition, and pregnancy rates following timed breeding.
|
| ADME/Pharmacokinetics |
Fluorogestone acetate has a molecular weight of 406.49 and a molecular formula of C₂₃H₃₁FO₅. As a lipophilic steroid, it is well absorbed after administration and distributes to target tissues including the reproductive tract. The compound is metabolized in the liver and excreted primarily via the bile and urine. Its pharmacokinetics support once-daily or implant-based administration protocols.
|
| Toxicity/Toxicokinetics |
Fluorogestone acetate is generally well-tolerated at recommended doses in veterinary applications. As a synthetic progestin, it may cause side effects related to its hormonal activity, including effects on the reproductive cycle and potential impacts on fertility. Standard safety assessments for veterinary pharmaceuticals have been conducted to establish safe use guidelines.
|
| References | |
| Additional Infomation |
Flurogestone acetate is a corticosteroid hormone. It is a synthetic fluorinated steroid used as a progestin.
Fluorogestone acetate is a veterinary pharmaceutical used for reproductive management in cattle. It is available in various formulations including intravaginal implants and injectable preparations for estrous synchronization. The compound’s ability to inhibit ovulation and synchronize estrous cycles makes it a valuable tool in livestock breeding programs. |
| Molecular Formula |
C23H31FO5
|
|---|---|
| Molecular Weight |
406.49
|
| Exact Mass |
406.215
|
| CAS # |
2529-45-5
|
| Related CAS # |
337-03-1 (parent)
|
| PubChem CID |
10476437
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
526.7±50.0 °C at 760 mmHg
|
| Melting Point |
267.5ºC
|
| Flash Point |
272.3±30.1 °C
|
| Vapour Pressure |
0.0±3.1 mmHg at 25°C
|
| Index of Refraction |
1.548
|
| LogP |
1.93
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
29
|
| Complexity |
820
|
| Defined Atom Stereocenter Count |
7
|
| SMILES |
CC(=O)[C@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2CCC4=CC(=O)CC[C@@]43C)F)O)C)OC(=O)C
|
| InChi Key |
JKQQZJHNUVDHKP-FQJIPJFPSA-N
|
| InChi Code |
InChI=1S/C23H31FO5/c1-13(25)22(29-14(2)26)10-8-17-18-6-5-15-11-16(27)7-9-20(15,3)23(18,24)19(28)12-21(17,22)4/h11,17-19,28H,5-10,12H2,1-4H3/t17-,18-,19-,20-,21-,22-,23-/m0/s1
|
| Chemical Name |
[(8S,9R,10S,11S,13S,14S,17R)-17-acetyl-9-fluoro-11-hydroxy-10,13-dimethyl-3-oxo-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-yl] acetate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~7.14 mg/mL (~17.57 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 0.71 mg/mL (1.75 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 7.1 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4601 mL | 12.3004 mL | 24.6009 mL | |
| 5 mM | 0.4920 mL | 2.4601 mL | 4.9202 mL | |
| 10 mM | 0.2460 mL | 1.2300 mL | 2.4601 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
